Of note, patchy hypervascularity as measured by CD31+ microvessels (vessels/mm2) was evident in some eribulin-treated PNET tumors, but did not result in an overall increase in tumor vascularity (CD31+ or NG2+ surface area), similar to published observations in breast cancer and sarcoma models (Funahashi et al, 2014; Taguchi et al, 2021) (Figs. EV2B and 2H). This evidence concerns the gene PECAM1 and breast carcinoma.